Rifaximin Treatment of Papulopustular Rosacea: Double- Blinded, Placebo-Controlled, Crossover Study

Trial Profile

Rifaximin Treatment of Papulopustular Rosacea: Double- Blinded, Placebo-Controlled, Crossover Study

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2014

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Bacterial infections; Rosacea
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Feb 2013 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 05 Feb 2013 Planned initiation date changed from 1 Jun 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 30 Jun 2012 Additional trial investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top